Compare BSRR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSRR | ALT |
|---|---|---|
| Founded | 1977 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.7M | 421.5M |
| IPO Year | 2001 | 2005 |
| Metric | BSRR | ALT |
|---|---|---|
| Price | $38.54 | $2.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $37.00 | $17.67 |
| AVG Volume (30 Days) | 53.7K | ★ 2.7M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | 10.28 | ★ 25.37 |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $11.74 | N/A |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $39.15 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $26.49 | $2.56 |
| 52 Week High | $39.00 | $7.73 |
| Indicator | BSRR | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 45.76 |
| Support Level | $36.00 | $2.87 |
| Resistance Level | N/A | $3.13 |
| Average True Range (ATR) | 0.78 | 0.12 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 85.20 | 47.56 |
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.